SG3 Management’s iShares Biotechnology ETF IBB Stock Holding History

SG3 Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,000	Closed	-$2.29M	–	1149
2021 Q4	$2.29M	Buy	+15,000	New	+$2.32M	0.05%	316

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

SG3 Management's IBB Position: Q1 2022 in Review

SG3 Management sold out of iShares Biotechnology ETF (IBB) in Q1 2022, closing a stake of 15,000 shares — an estimated $2.29M sold.

SG3 Management first reported a position in IBB in Q4 2021 and held it in 1 quarter. The position peaked at $2.29M in Q4 2021. 897 funds tracked by Wall St. Rank hold IBB as of Q1 2022.

SG3 Management reported no remaining iShares Biotechnology ETF position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 15,000 iShares Biotechnology ETF shares in Q1 2022, an estimated $2.29M.
SG3 Management first reported a position in iShares Biotechnology ETF in Q4 2021 and held it in 1 quarter.
SG3 Management's iShares Biotechnology ETF position peaked at $2.29M in Q4 2021.
897 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.